Affordable Access

Publisher Website

Acute lymphoblastic leukaemia

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
381
Issue
9881
Identifiers
DOI: 10.1016/s0140-6736(12)62187-4
Keywords
  • Review And Opinion
  • Seminar
Disciplines
  • Biology
  • Medicine
  • Pharmacology

Abstract

Summary Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments